| Literature DB >> 27610146 |
Mohammad Sarfaraz Alam1, Mohammad Sajid Ali1, Foziyah Zakir1, Nawazish Alam2, Mohammad Intakhab Alam1, Faruque Ahmad3, Masoom Raza Siddiqui4, Mohammad Daud Ali5, Mohammad Salahuddin Ansari6, Sarfaraz Ahmad1, Maksood Ali1.
Abstract
The aim of the present study was to investigate the potential of nanoemulsion formulation for topical delivery of Clobetasol propionate (CP) using algal oil (containing omega-3 fatty acids) as the oil phase. CP has anti-inflammatory, immunomodulatory and antiproliferative activities. However, its clinical use is restricted to some extent due to its poor permeability across the skin. Algal oil was used as the oil phase and was also exploited for its anti-inflammatory effect along with CP in the treatment of inflammation associated with dermatitis. Nanoemulsion formulations were prepared by aqueous phase titration method, using algal oil, tween 20, PEG 200 and water as the oil phase, surfactant, co-surfactant and aqueous phase respectively. Furthermore, different formulations were subjected to evaluate for ex-vivo permeation and in-vivo anti-inflammatory, irritation and contact dermatitis studies. The optimized nanoemulsion was converted into hydrogel-thickened nanoemulsion system (HTN) using carbopol 971 and had a viscosity of 97.57 ± 0.04 PaS. The optimized formulation had small average diameter (120 nm) with zeta potential of -37.01 mV which indicated good long-term stability. In-vivo anti-inflammatory activity indicated 84.55% and 41.04% inhibition of inflammation for drug loaded and placebo formulations respectively. The assessment of skin permeation was done by DSC and histopathology studies which indicated changes in the structure of epidermal membrane of skin. Contact dermatitis reveals that the higher NTPDase activity in the treatment with the CP-loaded nanoemulsion could be related to the higher anti-inflammatory effect in comparison with placebo nanoemulsion gel.Entities:
Keywords: Algal Oil; Anti-inflammatory study; Clobetasol Propionate; Contact Dermatitis; Nanoemulsion
Year: 2016 PMID: 27610146 PMCID: PMC4986117
Source DB: PubMed Journal: Iran J Pharm Res ISSN: 1726-6882 Impact factor: 1.696
Miscibility of algal oil with surfactants and co-surfactants
|
| ||||
|---|---|---|---|---|
|
|
|
|
|
|
| 1 | Tween 20 | Clear | Ethanol | Turbid |
| 2 | Tween 80 | Turbid | Transcutol P | Turbid |
| 3 | Lecithin | Turbid | PEG 200 | Clear |
| 4 | Unitop 100 | Turbid | Pleurol oleique | Turbid |
Figure 1Pseudo-ternary phase diagram for optimizing nanoemulsion formulation
Composition of various CP loaded nanoemulsions
|
|
|
|
|
|
|---|---|---|---|---|
| A1 | 7 | 50 | 43 | 0.05 |
| A2 | 8 | 46 | 46 | 0.05 |
| A3 | 10 | 55 | 35 | 0.05 |
| B1 | 5 | 45 | 45 | 0.05 |
| B2 | 5 | 40 | 55 | 0.05 |
| B3 | 7 | 57 | 36 | 0.05 |
| B4 | 9 | 50 | 41 | 0.05 |
| C1 | 10 | 51 | 39 | 0.05 |
| C2 | 15 | 57 | 28 | 0.05 |
| C3 | 20 | 61 | 19 | 0.05 |
Physical stability studies of drug loaded formulations
|
|
|
|
|
|---|---|---|---|
| A1 | Passed | Failed | Failed |
| A2 | Passed | Passed | Passed |
| A3 | Failed | Failed | Passed |
| B1 | Passed | Passed | Passed |
| B2 | Passed | Passed | Passed |
| B3 | Failed | Passed | Failed |
| B4 | Passed | Passed | Passed |
| C1 | Passed | Passed | Passed |
| C2 | Passed | Passed | Passed |
| C3 | Failed | Failed | Failed |
Evaluation of various drug loaded formulations
|
|
|
|
|
|
|
|
|---|---|---|---|---|---|---|
| A2 | 172 | 0.671 | -24.34 | 4.55 ±0.03 | 5.30 | 1.402 |
| B1 | 120 | 0.325 | -37.01 | 4.42 ±0.02 | 5.40 | 1.412 |
| B2 | 135 | 0.512 | -12.39 | 3.91 ±0.03 | 5.34 | 1.415 |
| C1 | 258 | 0.413 | -25.13 | 4.67 ±0.05 | 5.27 | 1.424 |
Figure 2Average droplet size of nanoemulsion formulation B1.
Figure 3Ex-vivo permeation nanoemulsion study of formulations
Ex-vivo permeation parameter of CP loaded nanoemulsion formulation and control
|
|
|
|
|
|---|---|---|---|
| A2 | 7.27 | 0.014 | 3.69 |
| B1 | 10.27 | 0.020 | 5.22 |
| B2 | 6.56 | 0.013 | 3.33 |
| C1 | 5.03 | 0.010 | 2.55 |
| Control | 1.96 | 0.003 | 1 |
Figure 4Cryo-electron microscopic images of formulations; A = Placebo; B = Drug loaded nanoemulsion
Evaluation of hydrogel thickened system
|
|
|
|
|
|
|
|---|---|---|---|---|---|
| 1 | 0.4 | 64.79 ± 0.03 | 5.15 ± 0.05 | 8.69 | 0.25 |
| 2 | 0.8 | 73.44 ± 0.01 | 5.43 ± 0.03 | 5.12 | 0.34 |
| 3 | 1 | 97.57 ± 0.04 | 5.55 ± 0.01 | 3.93 | 0.57 |
Figure 5DSC study of rat skin (A) and CP-loaded nanoemulsion treated skin (B).
Figure 6Histological findings of skin biopsies from wistar rats; control (A), treated with nanoemulsion (B
Anti-inflammatory effects of drug loaded and placebo nanoemulsion gel in carrageenan-induced rat paw edema
|
|
|
|
|
|
|
|
|---|---|---|---|---|---|---|
| I | Control | 6 | 180.0±12.3 | 1 | 29.2±2.3 | |
| (carrageenan only) | 2 | 43.01±4.2 | ||||
| 3 | 76.25±3.3 | |||||
| 6 | 59.11±3.7 | |||||
| 12 | 39.3±3.01 | |||||
| II | Drug loaded | 6 | 190±10.01 | 1 | 25.5±2.4 | 12.67 |
| nanoemulsion hydrogel | 2 | 33.15±2.8 | 22.92 | |||
| 3 | 46.20±4.1 | 39.40 | ||||
| 6 | 14.10±1.8 | 76.16 | ||||
| 12 | 6.09 ±1.2 | 84.55 | ||||
| III | Placebo | 6 | 195.0±12.3 | 1 | 27.3 ±3.1 | 6.50 |
| nanoemulsion hydrogel | 2 | 36.6 ±3.7 | 14.90 | |||
| 3 | 53.19 ±3.4 | 30.37 | ||||
| 6 | 36.12 ±3.1 | 38.89 | ||||
| 12 | 23.17±2.5 | 41.04 |
N = Number of rats in each group; SD = Standard deviation
Skin irritation score of the placebo nanoemulsion, drug loaded nanoemulsion and marketed cream
|
|
|
|
|
|
|
|
|
|
|---|---|---|---|---|---|---|---|---|
| 1 | Drug loaded nanoemulsion hydrogel | 1 | 1 | 3 | 2 | 1 | 2 | 1.66 ± 0.81 |
| 2 | Placebo nanoemulsion hydrogel | 2 | 0 | 2 | 0 | 1 | 2 | 0.83±0.75 |
Figure 7ATP (7a) and ADP (7b) hydrolysis in lymphocytes obtained from the control group (C), contact dermatitis group (D), groups with dermatitis treated with placebo nanoemulsion, and drug loaded nanoemulsion. Data were analyzed statistically by one-way ANOVA followed by the Tukey-Kramer test (a) and Kruskal-Wallis Test (b), (p < 0.05